Male Breast Cancer Completed Phase 1 / 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00258349Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerTreatment
NCT00331552Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast CancerTreatment